MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.29 -4.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.26

Max

1.37

Põhinäitajad
By Trading Economics
Sissetulek	-4.5M -52M
Müük	-1.2M 1.9M
Aktsiakasum	-0.44
Kasumimarginaal	-2,803.925
Töötajad	181
EBITDA	10M -42M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+357.04% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	8. mai 2025

Turustatistika
By TradingEconomics
Turukapital	26M 143M
Eelmine avamishind	5.73
Eelmine sulgemishind	1.29

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

0.8624 / 1.49 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Intel, AppFolio

24. apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. apr 2025, 23:37 UTC

Peamised uudised

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. apr 2025, 23:36 UTC

Peamised uudised

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. apr 2025, 23:13 UTC

Peamised uudised

Tulu

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. apr 2025, 23:09 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. apr 2025, 22:51 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. apr 2025, 22:48 UTC

Peamised uudised

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. apr 2025, 22:38 UTC

Market Talk

Tulu

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. apr 2025, 22:24 UTC

Market Talk

Tulu

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. apr 2025, 22:23 UTC

Tulu

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. apr 2025, 22:11 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

24. apr 2025, 22:11 UTC

Market Talk

Tulu

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. apr 2025, 22:09 UTC

Peamised uudised

Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. apr 2025, 22:00 UTC

Market Talk

Tulu

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. apr 2025, 21:39 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. apr 2025, 21:23 UTC

Peamised uudised

Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. apr 2025, 21:04 UTC

Tulu

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. apr 2025, 21:02 UTC

Tulu

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

357.04% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD 357.04%

Kõrge 12 USD

Madal 2.5 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.8624 / 1.49Toetus ja vastupanu

Bullish events outweigh bearish events.

All events are bullish.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.